Brief: Processa Doses Patient In Amended Phase 1B Protocol For PCS6422 Combined With Capecitabine

Processa Pharmaceuticals

20/04/2022 14:03

April 20 (Reuters) - Processa Pharmaceuticals Inc  PCSA.O :
    * PROCESSA PHARMACEUTICALS DOSES FIRST PATIENT IN AMENDED
PHASE 1B
PROTOCOL FOR PCS6422 COMBINED WITH CAPECITABINE (NEXT GENERATION
CAPECITABINE)

Source text for Eikon:  ID:nGNX5b5ML5 
Further company coverage:  PCSA.O 

 ((Reuters.Briefs@thomsonreuters.com;))